A retrospective review ( n = 2,247) was conducted from July 1st to October 1st 2010 to determine validity of the Missouri Alliance for Home Care Fall Risk Assessment Tool (MAHC-10). Fall risk was identified by a MAHC-10 score ≥ 4. Two sample t test, chi-square, logistic regression, and ROC curve analyses were performed. Fallers (6.35 ± 1.7, n = 195) and nonfallers (5.70 ± 1.9, n = 2,052) had significantly different ( p = .011) MAHC-10 scores. The MAHC-10 cutoff score of 4 demonstrated 96.9% sensitivity and 13.3% specificity; however, ROC curve analyses revealed a cutoff score of 6 maximized combined sensitivity and specificity. The MAHC-10 is valid for fall risk screening in the home health setting; however, a cutoff score of 6 may more accurately predict fall risk.

Cancer is the second leading cause of death in the United States, with more than 1 million new cancer cases diagnosed each year. Yet, survival from cancer has been increasing dramatically, with more than 2 million fewer cancer deaths during the past 2 decades than in previous decades. Physical therapists are familiar with the side effects of common chemotherapies and radiation therapy, but new immunotherapy drugs coming to the market have the potential to completely change the cancer treatment landscape. They provide new hope for cures that previously were not possible, but they also have their own side effects and toxicity issues. Because of their recent introduction to the market, no studies have examined the effects of immunotherapies on cancer rehabilitation, yet it is an essential question. The purpose of this article is to review 2 categories of new cancer immunotherapy treatments: checkpoint inhibitors and chimeric antigen receptor T cells. The physiological mechanism, known side effects, and toxicities are reviewed. We discuss the implications for physical therapists caring for cancer survivors and propose conservative interventions, ensuring that therapists provide the highest level of care for our patients with cancer. The purpose of this article is to inform the rehabilitation professional and set the baseline understanding for subsequent research studies elucidating the long-term effect of immunotherapies on cancer rehabilitation.